abrdn Life Sciences Investors
HQL
47 hedge funds and large institutions have $51.1M invested in abrdn Life Sciences Investors in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
15% more funds holding
Funds holding: 41 → 47 (+6)
7% more capital invested
Capital invested by funds: $47.6M → $51.1M (+$3.54M)
1.16% less ownership
Funds ownership: 12.74% → 11.58% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Advisors Asset Management
Monument,
Colorado
|
+$1.05M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$1.02M |
| 3 |
Morgan Stanley
New York
|
+$953K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$284K |
| 5 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
+$278K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$1.89M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$825K |
| 3 |
LPL Financial
San Diego,
California
|
-$780K |
| 4 |
NIM
Needham Investment Management
New York
|
-$451K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$190K |
HQL Hedge Fund Activity: Q2 2017 in Review
47 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2017, worth a combined $51.1M — up 7.4% from $47.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new HQL positions and 2 closed out — a net gain of 6 holders — while 18 added to existing stakes and 12 trimmed.
The largest buyer was Advisors Asset Management, opening a new position worth an estimated $1.05M. The largest seller was Citigroup, cutting an estimated $1.89M.
- 47 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2017, up from 41 in Q1 2017.
- Funds reported $51.1M of abrdn Life Sciences Investors stock for Q2 2017, up 7.4% quarter-over-quarter.
- 8 funds opened new abrdn Life Sciences Investors positions in Q2 2017 and 2 closed out, a net change of +6 holders.
- The largest abrdn Life Sciences Investors buyer in Q2 2017 was Advisors Asset Management, an estimated $1.05M added.
- The largest abrdn Life Sciences Investors seller in Q2 2017 was Citigroup, an estimated $1.89M sold.
Based on aggregated 13F filings for Q2 2017.